Fig. 2From: Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendotheliomaBaseline magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) studies for a 22-year-old man (“Case 2”) with pseudomyogenic hemangioendothelioma. a Baseline contrast-enhanced, fat-saturated T1-weighted axial MR image of the right thigh demonstrates multifocal enhancing lesions in the distal femoral metadiaphysis (short white arrow) and vastus intermedius muscle and subcutaneous fat. b PET-CT fusion image through the distal femurs demonstrates corresponding hypermetabolic activity. Restaging examinations after two cycles of gemcitabine and docetaxel (not shown) did not demonstrate any significant responseBack to article page